This statement is false. The benefits of prostate cancer screening with Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) are controversial and depend heavily on age and overall health. Major studies have shown that screening can reduce prostate cancer mortality in certain populations (like men aged 55-69), but it also leads to significant overdiagnosis and overtreatment of indolent cancers that would never have caused harm. For men over 70 or those with a life expectancy of less than 10-15 years, the potential harms of screening (including complications from unnecessary biopsies and treatments) generally outweigh the benefits. Therefore, screening decisions should be individualized through shared decision-making between the patient and physician, considering the patient's age, family history, and overall health status.

Break down complex topics into smaller, manageable chunks for easier recall.

Zambia

• loveness Phiri – 801 pts

• Visual Pathway Lesions
• Positive and Negative Symptoms
• Hallucinations and Delusions
• Antipsychotic Medications
• Emergency: Environmental Emergencies